Please wait ...

Details for receptor: FLT3

EndoNet ID: ENR00874

To link to the content of EndoNet use the EndoNet ID that is given on the detail pages in the format ENX0000, where X is a place holder for the type of the component (e. g. R for receptor or C for anatomical structure).
As URL for the linking append this ID to the detail page for this type of component.
For an hormone that would be:

It is also possible to use the search of EndoNet to link to the right detail page. The URL should look like
If the search pattern is unambigious the user is directed to the corresponding detail page.


  • FL cytokine receptor
  • tyrosine-protein kinase receptor FLT3
  • stem cell tyrosine kinase 1
  • STK-1
  • CD135 antigen
  • STK1
  • FLK2
  • FLT3

General information

  • FMS-like tyrosine kinase-3 (FLT3) is a member of the PDGF-R subfamily of receptor tyrosine kinases. [1]

Links to other resources

UniProt P36888
Ensembl ENST00000380987

Binding hormones

  • FLT3-Ligand
    • FTL3 is a cell-surface receptor for the cytokine FLT3LG. [2]

Anatomical structures with this receptor

  • hematopoietic_stem_cell

    Induced phenotypes

    • hematopoiesis
      • The accumulated data clearly point to FLT3 as an important receptor in early hematopoiesis. [1]
    • Acute myeloid leukemia
      • Deregulated tyrosine kinase activity has long been implicated in the molecular pathogenesis of cancer, including leukemia, and mutant forms of KIT, ABL, and platelet-derived growth factor receptor (PDGF-R) number among the constitutively activated tyrosine kinases that have been identified as causative factors in specific hematologic malignancies. [1]
      • FMS-like tyrosine kinase-3 (FLT3), a member of the PDGF-R subfamily of receptor tyrosine kinases, is the most recent major addition to this list [1]
      • A number of FLT3 activating mutations have been found in leukemia patients and human leukemia-derived cell lines. [1]
      • FLT3 activating mutations occur in 30% of AML cases and are therefore the most common molecular abnormality in that disease. [1]
    • In human hematopoietic cells, FLT3 expression is restricted to the CD34-positive fraction of bone marrow and a smaller fraction of CD34-negative cells destined to become dendritic cells. [1]